|
BioMimetic Therapeutics' GEM might not attract the attention of admirers, but it does attract cells promoting tissue and bone growth when it is applied to damaged tissue or a bone fracture. The company's lead product candidates, orthopedic bone grafts GEM OS1 and GEM OS2, are combination drug and medical devices that contain a human tissue growth factor with a synthetic bone matrix. BioMimetic Therapeutics is hoping to develop the GEM technology as a treatment for various fractures, where its bone matrix can be used to repair, reinforce, or fuse broken bones. The company is focused on orthopedic, spine, and sports injuries. The company has sold its commercial GEM 21S dental product.
|
| | | Contact Information | |
Address: |
389-A Nichol Mill Ln.
Franklin, TN 37067
| | Phone: | 615-844-1280 | | Fax: | 615-844-1281 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 3.10 M | | Revenue Growth (1 yr): | (-55.20%) | | Employees (2008): | 88 | | Employee Growth (1 yr): | 1.10% |
|
|
Key People
| | • |
Chairman:
Larry W. Papasan
| | • |
President, CEO, and Director:
Samuel E. Lynch
| | • |
EVP Orthopedics and COO:
Steven N. (Steve) Hirsch
|
|
|
